Allied Market Research published a report, titled, “Mycoplasma Testing Market By Product (Instruments, Kits & Reagents, and Services), By Technology (PCR, ELISA, Microbial Culture Techniques, and Enzymatic Methods), By Application (Cell Line Testing, Virus Testing, End of Production Cells Testing, and Others), By End User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032.” According to the report, the global mycoplasma testing industry was estimated at $0.7 billion in 2022, and is anticipated to hit $2.2 billion by 2032, registering a CAGR of 11.7% from 2023 to 2033.
Request Sample Report- https://www.alliedmarketresearch.com/request-sample/11631
Prime determinants of growth
The growth of the global mycoplasma testing market is driven by factors such as increase in use of mycoplasma testing products due to surge in demand for biologics and biosimilars, rise in technological advancements, and the adoption of advanced mycoplasma testing products. However, the high cost of mycoplasma testing products and services and lack of skilled laboratory technicians are hampering the mycoplasma testing market growth. On the contrary, technological advancement in mycoplasma testing such as development of ready-to-use culture media and nucleic acid amplification technique, and emergence of biopharmaceutical companies in developing countries such as China and India are expected to offer remunerative opportunities for expansion of the mycoplasma testing market during the forecast period.
Impact of Covid-19 on Mycoplasma Testing Market:
- Due to the COVID-19 pandemic and the subsequent global lockdowns, the mycoplasma testing market faced a downturn.
- However, as the global situation started ameliorating, the demand for mycoplasma testing has increased in biotechnology and biopharmaceutical industries and increase in development of rapid and accurate testing methods further contribute towards the market growth. This, in turn, presented various growth opportunities for companies operating in the mycoplasma testing market.
Procure Complete Report (400 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/mycoplasma-testing-market
The kits & reagents segment to maintain its leadership status throughout the forecast period
Based on product, the kits & reagents segment held the highest market share in 2022, accounting for more than half of the global mycoplasma testing market revenue, and is estimated to maintain its leadership status throughout the forecast period. This segment is also projected to manifest the highest CAGR of 12.2% from 2023 to 2032, as it is easy to use, provide rapid results as compared to traditional mycoplasma testing methods, and it is available in various technologies such as PCR based kits and reagents and ELISA based kits and reagents.
The PCR segment to maintain its leadership status throughout the forecast period
Based on technology, the PCR segment held the highest market share in 2022, accounting for nearly two-fifths of the global mycoplasma testing market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to adoption of advanced PCR based products in biopharmaceutical industries and contract research organizations, and high success rate for mycoplasma detection. However, the ELISA segment is projected to manifest the highest CAGR of 12.7% from 2023 to 2032, owing to the use of ELISA based mycoplasma testing products in various pharmaceutical industries as it offers accurate and rapid results.
The cell line testing segment to maintain its lead position during the forecast period
Based on application, the cell line testing segment accounted for the largest share in 2022, contributing to nearly half of the global mycoplasma testing market revenue and is estimated to maintain its leadership status throughout the forecast period. This segment is also projected to maintain highest CAGR of 12.5% during the forecast period, owing to surge in cell line mycoplasma contamination and increase in use of mycoplasma testing products for cell line testing in cell banks, biopharmaceutical companies, and contract research organizations.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/11631
North America to maintain its dominance by 2032
Based on region, North America held the highest market share in terms of revenue in 2022, accounting for more than two-fifths of the global mycoplasma testing market revenue and is likely to dominate the market during the forecast period, owing to rise in technological advancements, increase in demand for biologics and biosimilars mycoplasma testing. However, the Asia-Pacific region is expected to witness the fastest CAGR of 13.9% from 2023 to 2032, owing to surge in the adoption of PCR and ELISA based mycoplasma testing products and emergence of biopharmaceuticals companies in this region.
Leading Market Players:
- ATCC
- Bionique Testing Laboratories LLC
- Bio-Rad Laboratories, Inc.
- Charles River Laboratories
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd.
- InvivoGen
- Lonza
- Norgen Biotek Corp.
- Thermo Fisher Scientific Inc.
The report provides a detailed analysis of these key players of the global mycoplasma testing market. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
𝐎𝐮𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐘𝐨𝐮 𝐀𝐧𝐬𝐰𝐞𝐫 𝐭𝐨 𝐁𝐞𝐥𝐨𝐰 𝐌𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧:
- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?
𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤
- North America
(U.S., Canada, Mexico)
- Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
- LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
